8-K
filed August 7, 2024, 7:59 PM ET
ticker SYRE
CIK 0001636282
earnings
confidence high
sentiment positive
materiality 0.75
Spyre Q2 net loss narrows to $38.8M; SPY001 Phase 1 dosed, interim data by year-end
Spyre Therapeutics, Inc.
2024-Q2 EPS reported
-$2.02
- Net loss narrowed to $38.8M in Q2 2024 from $217.1M in Q2 2023; cash and securities $426.3M.
- R&D expenses increased to $32.6M (vs $17.4M) driven by IBD pipeline advancement; no acquired IPR&D in Q2 2024.
- SPY001 (anti-α4β7) Phase 1 dosing initiated; interim proof-of-concept data expected by end of 2024 for every-8-12 week dosing.
- SPY002 (anti-TL1A) two candidates with subnanomolar potency; FIH trials in H2 2024 with interim data in H1 2025.
- SPY003 (anti-IL-23) development candidate nominated; FIH trial expected in H1 2025; $426M cash runway into 2027.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001636282-24-000053
- form_type
- 8-K
- ticker
- SYRE
- cik
- 0001636282
- company_name
- Spyre Therapeutics, Inc.
- filed_at
- 2024-08-07T23:59:59+00:00
- discovered_at
- 2026-05-14T18:03:13.897545+00:00
- generated_at
- 2026-05-31T11:47:37.102699+00:00
- sec_items
- ["2.02", "9.01"]
- event_type
- earnings
- sentiment
- positive
- materiality_score
- 0.75
- calibrated_materiality_score
- 0.75
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001636282-24-000053
- json_url
- https://secwatch.observer/filing/0001636282-24-000053.json
- markdown_url
- https://secwatch.observer/filing/0001636282-24-000053.md
- text_url
- https://secwatch.observer/filing/0001636282-24-000053.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1636282/000163628224000053/0001636282-24-000053-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1636282/000163628224000053/syre-20240807.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
CRDO
Credo Q4 revenue $437M (+157% YoY); guides Q1 $465-475M; CEO awarded 1.44M performance-based RSUs
Credo Technology Group Holding Ltd
June 1, 2026, 4:08 PM ET
earnings
Items 2.02, 5.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
DAVEY TREE EXPERT CO
Davey Tree Q1 net loss widens to $10.7M; revenue flat at $435.8M
DAVEY TREE EXPERT CO
June 1, 2026, 1:50 PM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
RMCF
Rocky Mountain Chocolate Factory Q4 revenue down 24% to $6.8M; net loss per share widens to $0.38
Rocky Mountain Chocolate Factory, Inc.
June 1, 2026, 9:15 AM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
SAIC
SAIC Q1 adj EPS $3.23 beats $1.92; raises FY adj EBITDA and EPS guidance
Science Applications International Corp
June 1, 2026, 6:55 AM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
FNGR
FingerMotion FY2026 revenue down 32% to $24.1M; net loss widens to $7.0M
FingerMotion, Inc.
May 29, 2026, 5:12 PM ET
earnings
Items 2.02, 7.01, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
BKE
Buckle Q1 net income $46.9M ($0.93/share), sales up 6.1% to $288.7M
BUCKLE INC
May 29, 2026, 3:38 PM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
HIND
Vyome Q1 net loss $963K, cash $8.8M, inks JAK inhibitor licensing deal with Impetis
Vyome Holdings, Inc
May 29, 2026, 8:42 AM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
ELMT
Elmet Group Q1 revenue up 21% to $56M; adjusted EBITDA +106% to $9.2M; record backlog $113M
Elmet Group Co.
May 29, 2026, 8:05 AM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.